Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,337 | -3,014 | -1,162 | -4,762 | -2,365 |
| Depreciation Amortization | 1 | 1 | 1 | 7 | 7 |
| Accounts payable and accrued liabilities | 71 | 205 | -363 | -569 | -295 |
| Other Working Capital | 893 | 734 | -260 | 143 | -49 |
| Other Operating Activity | 915 | 457 | 690 | 1,897 | 330 |
| Operating Cash Flow | $-2,456 | $-1,617 | $-1,093 | $-3,284 | $-2,372 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -186 | -152 | -82 | N/A | -244 |
| Debt Issued | 1,525 | 995 | 455 | 2,853 | 2,303 |
| Debt Repayment | N/A | N/A | N/A | -100 | N/A |
| Common Stock Issued | 700 | 700 | 700 | -5 | N/A |
| Other Financing Activity | 0 | 0 | 0 | 0 | -100 |
| Financing Cash Flow | $2,039 | $1,543 | $1,073 | $2,748 | $1,959 |
| Exchange Rate Effect | 0 | 0 | 0 | -1 | 0 |
| Beginning Cash Position | 490 | 490 | 490 | 1,027 | 1,027 |
| End Cash Position | 73 | 417 | 470 | 490 | 614 |
| Net Cash Flow | $-417 | $-73 | $-20 | $-537 | $-413 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,456 | -1,617 | -1,093 | -3,284 | -2,372 |
| Free Cash Flow | -2,456 | -1,617 | -1,093 | -3,284 | -2,372 |